SPRB
SPRUCE BIOSCIENCES, INC.
Next earnings Aug 12, 2026 (after close) · consensus $-6.23 EPS
Last earnings +1.6% on 2026-05-13
$55.11
▲ +4.43%$55.11▲ +949.71%
over 1Y
L $5.25EODHDH $182.60
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+4.4%
1W+0.7%
1M+11.3%
3M-12.6%
YTD-39.2%
1Y+949.7%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 11 analysts
Buy
Conservative balance sheet (liabilities/equity 0.25x); but revenue fell -100.0% YoY.
Revenue (FY2025) $0.00 · FY2025
SPRUCE BIOSCIENCES, INC. shows $0.00 in FY2025 revenue (-100.0% YoY), and -91.7% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | $0.00 | $10.1M | $4.91M | $0.00 |
| Gross profit | — | — | — | — | — |
| Operating income | -$42.1M | -$47.3M | -$52.0M | -$56.2M | -$36.5M |
| Net income | -$42.3M | -$46.2M | -$47.9M | -$53.0M | -$39.0M |
| Diluted EPS | -$1.81 | -$1.96 | -$1.24 | -$96.40 | -$50.83 |
| Net margin | — | — | -475.0% | -1079.9% | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$26.7M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-51.5%
FCF yield-44.1%
Quality & risk
ROIC (est.)-67.8%
Free cash flow-$33.3M
Total debt$0.00
Net cash$48.9M
Altman Z-Score-4.64 distress
Piotroski F-Score5/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-96.8%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — agreement terminated (2026-03-20). Worth a closer look.
Recent filings
all on EDGAR ↗4Period ending 2026-05-212026-05-26open ↗4Period ending 2026-05-212026-05-26open ↗4Period ending 2026-05-212026-05-26open ↗4Period ending 2026-05-212026-05-26open ↗4Period ending 2026-05-212026-05-26open ↗8-KPeriod ending 2026-05-212026-05-26open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗S-8Filing2026-05-13open ↗10-QPeriod ending 2026-03-312026-05-13open ↗
Frequently asked
- Is SPRUCE BIOSCIENCES, INC. (SPRB) a buy?
- SPRB currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.25x); but revenue fell -100.0% YoY.
- What is SPRUCE BIOSCIENCES, INC.'s quality score?
- SPRB scores 46.94871794871795/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001683553, latest 10-Q filed 2026-05-13) · EODHD · as of 6/26/2026, 8:34:35 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.